Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT ID: NCT01577381


Title
A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration
Purpose
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
Details
The trial was terminated early on April 12, 2013 due to an organizational decision, which was not based on safety or efficacy concerns. Subjects who were already enrolled into the study were followed.
Conditions
Age-Related Maculopathy
Keywords
Phase 2, Advanced Dry Age-Related Macular Degeneration, Geographic Atrophy, RN6G
Source
Pfizer
Sponsors
Pfizer
Status
Terminated
Acronym
Last Updated
15 Feb 2016
URL
Official Link
Locations
United States, Germany, United Kingdom